CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions
Related Posts
Shree S, Pike M, Yee LM, Levine L, Simhan H, Silver RM, Greenland P, Saade G, Bairey Merz CN, Chung J, Cleary EM, Grobman W,[...]
Wang C, He Y, Wang Y, Deng Z, Wang L, Li D. Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall[...]
Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Mozafarybazargany M, Hashemi A, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Branch[...]